| Literature DB >> 33811119 |
Anna Spreafico1,2, Aaron R Hansen1,2, Albiruni R Abdul Razak1,2, Philippe L Bedard1,2, Lillian L Siu3,2.
Abstract
Clinical trials represent a fulcrum for oncology drug discovery and development to bring safe and effective medicines to patients in a timely manner. Clinical trials have shifted from traditional studies evaluating cytotoxic chemotherapy in largely histology-based populations to become adaptively designed and biomarker-driven evaluations of molecularly targeted agents and immune therapies in selected patient subsets. This review will discuss the scientific, methodological, practical, and patient-focused considerations to transform clinical trials. A call to action is proposed to establish the framework for next-generation clinical trials that strikes an optimal balance of operational efficiency, scientific impact, and value to patients. SIGNIFICANCE: The future of cancer clinical trials requires a framework that can efficiently transform scientific discoveries to clinical utility through applications of innovative technologies and dynamic design methodologies. Next-generation clinical trials will offer individualized strategies which ultimately contribute to globalized knowledge and collective learning, through the joint efforts of all key stakeholders including investigators and patients. ©2021 American Association for Cancer Research.Entities:
Mesh：
Year: 2021 PMID： 33811119 PMCID： PMC8099154 DOI： 10.1158/2159-8290.CD-20-1301
Source DB: PubMed Journal: Cancer Discov ISSN： 2159-8274 Impact factor: 38.272